Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pre-AMNOG drugs wriggle off Germany's retrospective assessment hook, but no escape for Novartis

This article was originally published in Scrip

Executive Summary

All marketed products which had been netted by Germany's pricing and reimbursement agency to face a retrospective assessment could be off the hook under the new coalition government, which has proposed a change to the controversial AMNOG law abolishing benefit assessments for pre-AMNOG drugs. But the policy comes too late for the gliptin class, including Novartis' Galvus (vildagliptin), which has already been caught and weighed and now faces major price cuts.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC023633

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel